Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Non-small cell lung cancer • University of Michigan • EGFR+ • ALK+

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study met its endpoint of overall survival. Does this change your practice at all?

Answer from: Medical Oncologist at Community Practice

The PACIFIC study represents an important advancement for patients with unresectable, stage III NSCLC. The initial OS results were presented recently and demonstrated a significant improvement in survival for patients receiving durvalumab following chemoradiation. The median time has not been reach...

Comments

Medical Oncologist at Virginia Cancer Specialists
With even lower numbers of patients with ALK gene ...

Related Questions